The stock has a 36-month beta value of 1.79. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVDL is 85.15M, and at present, short sellers hold a 12.21% of that float. On May 08, 2024, the average trading volume of AVDL was 1.19M shares.
AVDL) stock’s latest price update
Avadel Pharmaceuticals plc (NASDAQ: AVDL) has seen a decline in its stock price by -2.36 in relation to its previous close of 18.62. However, the company has experienced a 0.11% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-29 that The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AVDL’s Market Performance
Avadel Pharmaceuticals plc (AVDL) has seen a 0.11% rise in stock performance for the week, with a 6.13% gain in the past month and a 18.05% surge in the past quarter. The volatility ratio for the week is 4.96%, and the volatility levels for the past 30 days are at 5.84% for AVDL. The simple moving average for the past 20 days is 3.44% for AVDL’s stock, with a 32.30% simple moving average for the past 200 days.
Analysts’ Opinion of AVDL
Many brokerage firms have already submitted their reports for AVDL stocks, with Oppenheimer repeating the rating for AVDL by listing it as a “Outperform.” The predicted price for AVDL in the upcoming period, according to Oppenheimer is $29 based on the research report published on March 05, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see AVDL reach a price target of $22, previously predicting the price at $20. The rating they have provided for AVDL stocks is “Buy” according to the report published on March 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to AVDL, setting the target price at $25 in the report published on March 05th of the current year.
AVDL Trading at 10.00% from the 50-Day Moving Average
After a stumble in the market that brought AVDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.77% of loss for the given period.
Volatility was left at 5.84%, however, over the last 30 days, the volatility rate increased by 4.96%, as shares surge +8.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.95% upper at present.
During the last 5 trading sessions, AVDL rose by +0.11%, which changed the moving average for the period of 200-days by +31.07% in comparison to the 20-day moving average, which settled at $17.65. In addition, Avadel Pharmaceuticals plc saw 28.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVDL starting from MCHUGH THOMAS S, who purchase 2,000 shares at the price of $14.50 back on Jan 16 ’24. After this action, MCHUGH THOMAS S now owns 80,500 shares of Avadel Pharmaceuticals plc, valued at $29,000 using the latest closing price.
McCamish Mark Anthony, the Director of Avadel Pharmaceuticals plc, sale 75,000 shares at $14.53 during a trade that took place back on Dec 28 ’23, which means that McCamish Mark Anthony is holding 67,025 shares at $1,089,750 based on the most recent closing price.
Stock Fundamentals for AVDL
Current profitability levels for the company are sitting at:
- -4.93 for the present operating margin
- 0.95 for the gross margin
The net margin for Avadel Pharmaceuticals plc stands at -5.73. The total capital return value is set at -0.61. Equity return is now at value -481.35, with -68.90 for asset returns.
Based on Avadel Pharmaceuticals plc (AVDL), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -3.81. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -13.94.
Currently, EBITDA for the company is -136.08 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 66.02. The receivables turnover for the company is 2.08for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.64.
Conclusion
To sum up, Avadel Pharmaceuticals plc (AVDL) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
